Novo plows ahead in Russia; NICE nod to Xarelto; India's Biocon sees profits fall; $31M payday for Auxilium execs;

@FiercePharma: ICYMI yesterday: Pfizer wins recommendation for Prevenar expansion in Europe. Story | Follow @FiercePharma

@EricPFierce: UAE-based Gulf Pharmaceuticals intends to build a $50M insulin plant in Ethiopia. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ex-Sanofi chief Viehbacher makes a $5M-plus severance deal. Article | Follow @CarlyHFierce

> Novo Nordisk ($NVO) says it is continuing with a plant in Russia, despite economic issues in the country, as it prepares itself for the future. Story

> The U.K. cost watchdog NICE has issued final guidance recommending Bayer blood thinner Xarelto to treat blood clots in patients who have had a heart attack. Release

> India's Biocon reported a 13% decline in net profit for the last quarter and says it will sell a 10% to 15% stake in its Syngene research unit. Report

> EU evaluators have recommended expanding approval of Novo Nordisk blood cancer treatment Jakavi to include polycythemia vera, a chronic incurable blood cancer. Report

> Hospira ($HSP) is recalling one lot of saline solution after human hair was found in a single unit. Report

Medical Device News

@FierceMedDev: Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Welch Allyn buys eye exam provider, signaling move into services. Article | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Weber; Bonjour, Bohuon? FiercePharma article | Follow @EmilyWFierce

> Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. More

> France's bioMérieux and Astute Medical join forces on acute kidney injury test. Article

Biotech News

@FierceBiotech: EuroBiotech: EU IPOs obliterate recent highs, U.K. VC funding tops $700M, Woodford backs microbiome play. Report | Follow @FierceBiotech

@JohnCFierce: Interviewed the CEO at the new CAR-T player. Their CSO also worked on Bellicum program. Story | Follow @JohnCFierce

@DamianFierce: $MDCO's Clive Meanwell has by far the best name among biopharma CEOs. At least until someone appoints Guy Smiley. | Follow @DamianFierce

> The Medicines Co.'s FDA-rejected cardio drug finds EU success. Report

> GlaxoSmithKline's Ebola vaccine rolls into Phase III as outbreak simmers. Article

And Finally... Half a dozen execs at Auxilium Pharmaceuticals will share $31 million after cashing in stock options and awards following the completion of the buyout by Endo International ($ENDP), including CEO Adrian Adams, who will get $15.5 million alone. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.